XML 205 R161.htm IDEA: XBRL DOCUMENT
v3.22.4

Liabilities related to business combinations and to non-controlling interests - Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests (Details) € in Millions, $ in Millions | 12 Months Ended |
--- | --- | ---
Dec. 31, 2022 EUR (€) | Dec. 31, 2021 EUR (€) | Dec. 31, 2020 EUR (€) | Dec. 31, 2022 USD ($)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | € 714 | € 605 | € 800 |  |
Payments made | (136) | (258) | (122) |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 5 | (4) | (35) |  |
Other movements | 0 | (14) | (10) |  |
Currency translation differences | 40 | 25 | (28) |  |
New transactions | 156 | 360 |  |  |
Ending balance | 779 | 714 | 605 |  |
Non-current liabilities related to business combinations and to non-controlling interests | 674 | 577 | 387 | [1] |
Current liabilities related to business combinations and to non-controlling interests | 105 | 137 | 218 | [1] |
Bayer contingent purchase consideration arising from the acquisition of Genzyme |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | 59 | 104 | 156 |  |
Payments made | (29) | (31) | (42) |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | (9) | (18) | 9 |  |
Other movements | 0 | 0 | (8) |  |
Currency translation differences | 5 | 4 | (11) |  |
New transactions | 0 | 0 |  |  |
Ending balance | 26 | 59 | 104 |  |
MSD contingent consideration (European vaccines business) |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | 269 | 312 | 385 |  |
Payments made | (79) | (75) | (78) |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 14 | 26 | 9 |  |
Other movements | 0 | 0 | 0 |  |
Currency translation differences | 0 | 6 | (4) |  |
New transactions | 0 | 0 |  |  |
Ending balance | 204 | 269 | 312 |  |
Shire contingent consideration arising from the acquisition of Translate Bio |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | 354 | 0 | 0 |  |
Payments made | 0 | 0 | 0 |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 2 | 19 | 0 |  |
Other movements | 0 | 0 | 0 |  |
Currency translation differences | 24 | 12 | 0 |  |
New transactions | 0 | 323 |  |  |
Ending balance | 380 | 354 | 0 |  |
Amunix |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | 0 | 0 | 0 |  |
Payments made | 0 | 0 | 0 |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | (2) | 0 | 0 |  |
Other movements | 0 | 0 | 0 |  |
Currency translation differences | 11 | 0 | 0 |  |
New transactions | 156 | 0 |  |  |
Ending balance | 165 | 0 | 0 |  |
Other |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Beginning balance | 32 | 189 | 259 |  |
Payments made | (28) | (152) | (2) |  |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) | 0 | (31) | (53) |  |
Other movements | 0 | (14) | (2) |  |
Currency translation differences | 0 | 3 | (13) |  |
New transactions | 0 | 37 |  |  |
Ending balance | € 4 | € 32 | € 189 |  |
Translate Bio |  |  |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] |  |  |  |  |
Contingent consideration liabilities | $ |  |  |  |  | $ 382
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B67 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2021-01-01 -Paragraph 93 -Subparagraph e -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_i&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount recognised for new contingent liabilities recognised in a business combination. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B67 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of contingent liabilities recognised in a business combination that were settled. [Refer: Contingent liabilities recognised in business combination] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B67 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent consideration liabilities. + References No definition available. + Details
Name: | sny_ContingentConsiderationLiabilities
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This account includes current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease through net exchange differences business combinations and noncontrolling interests. + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNoncontrollingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This account includes non-current portion of contingent considerations that satisfy the recognition criteria of IFRS 3 Business combinations, measured initially at their fair value as at the date of acquisition. This account also includes non-current portion of liabilities related to non-controlling interests. + References No definition available. + Details
Name: | sny_NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Other movements. + References No definition available. + Details
Name: | sny_OtherMovements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerContingentConsiderationArisingFromTheAcquisitionOfGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromTheAcquisitionOfTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_OtherLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_TranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |